Study: State Laws Shape Peptide Access in Sexual Medicine

Where you live may matter as much as what your doctor prescribes. A 2026 study published in Sexual Medicine suggests that access to peptide-based sexual medicine therapies across the United States is not simply a matter of federal approval status—it may be shaped in significant part by the healthcare delivery policies of individual states. For patients and clinicians navigating this evolving therapeutic landscape, that finding carries real-world consequences worth understanding.

What This Study Found

Researchers Quesada SG, Ahmed Z, Nakamura HS, and colleagues conducted a cross-sectional, state-level analysis encompassing all 50 U.S. states and the District of Columbia to evaluate what they termed the "access environment" for peptide-based sexual medicine therapies (Quesada et al., 2026). Rather than focusing on the regulatory status of individual peptides, the research team examined three structural proxy variables that reflect the clinical feasibility of care delivery:

• Telehealth prescribing permissiveness — the degree to which a state's regulations allow clinicians to initiate and manage care via telemedicine
• Nurse practitioner (NP) practice authority — whether NPs in a given state can practice independently or require physician oversight
• Availability of FDA-registered 503B outsourcing facilities — the number of compounding facilities normalized by state population

These three variables were coded on a standardized scale and combined to generate a composite Peptide Access Environment Score (PAES) for each state. PAES values ranged from a low of 0.33 to a high of 1.56—a nearly fivefold difference—demonstrating what the authors describe as "substantial interstate variability."

States were stratified into high-, moderate-, and low-access tiers. High-access environments clustered predominantly in the Northeast and West, while low-access states appeared most frequently in the South and parts of the Midwest. Regional differences in PAES were statistically significant (p < .001).

Perhaps most notably, researchers found meaningful discordance between telehealth permissiveness and compounding infrastructure. Multiple states permitted clinicians to initiate care via telehealth but lacked in-state 503B compounding facilities—potentially leaving patients with a prescription but no practical means of filling it locally. Conversely, other states had robust compounding capacity but maintained restrictive telehealth regulations, limiting the clinicians who could access that infrastructure on patients' behalf.

Clinical Significance

The study suggests that the structural mismatch between telehealth policy and compounding availability represents a meaningful barrier to care—one that may not be immediately visible to either patients or prescribers. A clinician practicing in a telehealth-permissive state may assume a patient has straightforward access to a compounded peptide therapy, when in fact the absence of nearby 503B-registered facilities creates logistical and regulatory friction.

For practitioners, the researchers generated what they describe as a "clinician-friendly framework" for identifying geographic disparities. The PAES methodology uses publicly available data and a transparent, reproducible approach—meaning clinicians could theoretically apply similar tools to assess and anticipate access challenges for patients in different locations.

NP practice authority emerged as another clinically relevant variable. In states where NPs operate under full practice authority, the workforce capable of prescribing peptide-based therapies is effectively larger—potentially improving appointment availability and reducing time-to-treatment. In states requiring physician oversight, care pathways may be longer or more administratively complex.

The authors were candid about the limitations of their methodology. The study relied on proxy measures rather than direct access data, excluded physician assistant autonomy as a variable, and could not account for within-state heterogeneity related to socioeconomic factors or urban-rural geography. Human behavioral data—such as actual prescription rates or patient-reported access barriers—was not incorporated. These are important caveats that future research will need to address.

Current Access and Compliance Context

The broader regulatory environment for compounded peptides remains dynamic. FDA-registered 503B outsourcing facilities operate under stricter oversight than traditional compounding pharmacies, and their geographic distribution is uneven across the country. Patients and clinicians should be aware that the regulatory status of specific peptide compounds can change, and that compliance with both federal and state-level regulations is essential when pursuing any compounded therapy.

The study did not evaluate the clinical efficacy or safety of any specific peptide, nor did it make recommendations about which therapies patients should pursue. Its contribution is structural and epidemiological: it maps the environment in which access decisions occur, independent of whether any particular peptide is or should be approved for a given indication.

Clinicians operating across state lines via telehealth platforms should familiarize themselves with both the prescribing laws of the states where their patients reside and the compounding infrastructure available in those states. The discordance identified in this study suggests that assuming uniformity across state lines may lead to unintentional gaps in care delivery.

What Patients Should Know

If you have been exploring peptide-based options within the context of sexual medicine—whether for hormonal support, tissue repair, or other applications your clinician has discussed—the findings of this study suggest that your geographic location may meaningfully affect your access to care, even if you have a qualified clinician willing to treat you.

Here are several practical takeaways based on what the research suggests:

• Ask your provider about compounding options in your state. Not all states have FDA-registered 503B facilities, and this can affect how and whether a compounded peptide therapy can be dispensed to you.
• Understand your state's telehealth rules. In some states, telehealth-initiated prescriptions for certain therapies may face additional regulatory requirements. A knowledgeable provider can help you navigate these.
• Work with credentialed, licensed practitioners. The complexity of the regulatory landscape makes it especially important to work with clinicians who are current on both federal and state-level compliance requirements for the therapies they offer.
• Geographic disparities are real but not necessarily permanent. State-level healthcare policies evolve. Advocacy, awareness, and informed patient engagement can contribute to closing the access gaps this research has identified.

It is also worth noting that this study does not advocate for any specific peptide therapy or suggest that patients seek out treatments outside of appropriate clinical oversight. The goal of understanding access environments is to help ensure that patients who could benefit from evidence-informed care under proper medical supervision are not arbitrarily excluded by structural policy gaps.

Finding a Qualified Provider

The geographic disparities documented in this research underscore the importance of connecting with practitioners who are not only knowledgeable about peptide-based therapies in sexual medicine, but also well-versed in the regulatory environment of your state. Whether you are in a high-access or low-access tier as defined by the PAES framework, working with a qualified, licensed clinician is the appropriate starting point for any conversation about these therapies.

The Peptide Association maintains a directory of vetted practitioners across the United States who are equipped to discuss evidence-based peptide therapies within the bounds of applicable regulations. Visit peptideassociation.org/find-a-doctor to find a qualified provider in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content summarizes published peer-reviewed research and should not be interpreted as an endorsement of any specific therapy, product, or clinical approach. Always consult a licensed healthcare provider before beginning any new treatment. Regulatory status of compounded therapies varies by state and is subject to change.

---

Citation (AMA format): Quesada SG, Ahmed Z, Nakamura HS, et al. Access without approval: state-level determinants of peptide availability in sexual medicine. Sexual Medicine. 2026;July. doi:10.1093/sexmed/qfag050. PMID: 42394939.